We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunoassay Developed for Histoplasmosis Diagnosis

By LabMedica International staff writers
Posted on 27 Jan 2011
An immunoassay, using purified deglycosylated antigen, has been developed to diagnose different manifestations of the fungal disease histoplasmosis. More...


The enzyme-linked immunosorbent assay (ELISA) detects antibodies to Histoplasma capsulatum, the causative agent of histoplasmosis, using metaperiodate treated purified histoplasmin (ptHMIN), the specific antigen of this fungus.

To evaluate the ELISA test clinical serum samples were selected randomly from the Immunodiagnostic Section Serum Bank, Laboratory of Mycology, Institute of Clinical Research Evandro Chagas, (Fiocruz; Rio de Janeiro, Brazil). Forty-four sera samples were tested from homologous histoplasmosis and 35 sera samples from other cases of mycoses. These included seven with paraccocidioidomycosis; eight for each of the following: aspergillosis sporotrichosis, and cryptococcosis cases, and four from coccidioidomycosis patients. Additionally, 36 negative control sera from healthy donors were collected and tested.

The results of the assay showed that the optical densities (ODs) were significantly higher in sera from 44 patients with histoplasmosis than in heterologous-infected samples evaluated. Differences in the means and comparisons of parameters indicate that the test effectively discriminates between negative and positive samples. The distribution of OD values varied in the clinical groups, but no statistical differences were found between them. The OD values are an indication of antibody levels in the patients' sera.

The overall test specificity was 96%, with sensitivities of 100% in acute disease, 90% in chronic disease, 86% in disseminated disease co-infected with Human Immunodeficiency Virus (HIV), 89% in disseminated infection in individuals without HIV infection, and 100% in mediastinal histoplasmosis. The authors of the study concluded that the high specificities, sensitivities, and simplicity of the ELISA support further development of a deglycosylated HMIN ELISA for clinical use and for monitoring the humoral immune response during therapy in patients with chronic and disseminated histoplasmosis.

Histoplasmosis is a disease caused when airborne spores of the fungus H. capsulatum are inhaled into the lungs, the primary infection site. This microscopic fungus, which is found throughout the world in river valleys and soil where bird or bat droppings accumulate, is released into the air when soil is disturbed by plowing fields, sweeping chicken coops, or digging holes. The clinical disease generally ranges from mild influenza-like illnesses to progressive, disseminated disease, which manifests mostly in immunocompromised individuals. The study was published on line on January 4, 2010, in the open access journal Microbiology Research.

Related Links:

Institute of Clinical Research Evandro Chagas





New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.